RxDoctor Payments Data

Tung Nguyen, MD

Internal Medicine · San Francisco, CANPI 1003871724

Payments from drug & device makers

$15,471in general payments, 2019–2025

Across 34 payments — averaging $455.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • The Institute Of Musculoskeletal Science And Education$13K
  • Camber Spine Technologies LLC$2K
  • E.r. Squibb & Sons, L.L.C.$97
  • AstraZeneca$93
  • GSK$42
  • AbbVie$38
  • plus $50 from 2 others

What the payments were for

  • Royalty or licence$11,80276%
  • Travel & lodging$2,39015%
  • Food & beverage$1,2798%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,471 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$10,504
Medicare patients
51
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate17$15,152
Breo ElliptaFluticasone/Vilanterol11$7,715
Tacrolimus11$2,940
Atorvastatin Calcium153$1,174
Albuterol Sulfate HfaAlbuterol Sulfate29$672
Omeprazole24$420
Gabapentin17$390
Tamsulosin Hcl18$347
Famotidine18$312
Metformin Hcl36$272
Amlodipine Besylate64$266
Metoprolol Succinate12$247
Finasteride16$241
Fluticasone Propionate22$206
Diclofenac Sodium12$156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$42$7,71511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →